146 related articles for article (PubMed ID: 35925768)
1.
Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
[TBL] [Abstract][Full Text] [Related]
2. Identification of second generation benzylidene chromanone analogues as novel, potent DHODH inhibitors in acute myeloid leukemia cells.
Abohassan M; Al Shahrani M; Rajagopalan P
J Biomol Struct Dyn; 2023; 41(13):6168-6177. PubMed ID: 35869648
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
[TBL] [Abstract][Full Text] [Related]
4. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
[TBL] [Abstract][Full Text] [Related]
5. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
[TBL] [Abstract][Full Text] [Related]
7. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
[TBL] [Abstract][Full Text] [Related]
8. Identification of Dihydroorotate Dehydrogenase Inhibitors─Indoluidins─That Inhibit Cancer Cell Growth.
Kawatani M; Aono H; Shimizu T; Ohkura S; Hiranuma S; Muroi M; Ogawa N; Ohishi T; Ohba SI; Kawada M; Yamazaki K; Dan S; Osada H
ACS Chem Biol; 2021 Nov; 16(11):2570-2580. PubMed ID: 34730931
[TBL] [Abstract][Full Text] [Related]
9. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
[TBL] [Abstract][Full Text] [Related]
10. A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.
Kamli H; Zaman GS; Shaikh A; Mobarki AA; Rajagopalan P
Oncol Res; 2022 Jan; 28(9):899-911. PubMed ID: 34353411
[TBL] [Abstract][Full Text] [Related]
11. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Sainas S; Giorgis M; Circosta P; Poli G; Alberti M; Passoni A; Gaidano V; Pippione AC; Vitale N; Bonanni D; Rolando B; Cignetti A; Ramondetti C; Lanno A; Ferraris DM; Canepa B; Buccinnà B; Piccinini M; Rizzi M; Saglio G; Al-Karadaghi S; Boschi D; Miggiano R; Tuccinardi T; Lolli ML
J Med Chem; 2022 Oct; 65(19):12701-12724. PubMed ID: 36162075
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods.
Higgins WT; Vibhute S; Bennett C; Lindert S
J Chem Inf Model; 2024 Jan; 64(2):435-448. PubMed ID: 38175956
[TBL] [Abstract][Full Text] [Related]
14. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
Front Oncol; 2022; 12():832816. PubMed ID: 35223511
[TBL] [Abstract][Full Text] [Related]
15. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia.
Zhang Y; Luo T; Ding X; Chang Y; Liu C; Zhang Y; Hao S; Yin Q; Jiang B
Biochem Biophys Res Commun; 2021 Apr; 547():162-168. PubMed ID: 33610916
[TBL] [Abstract][Full Text] [Related]
17. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Zhou J; Yiying Quah J; Ng Y; Chooi JY; Hui-Min Toh S; Lin B; Zea Tan T; Hosoi H; Osato M; Seet Q; Ooi LAG; Lindmark B; McHale M; Chng WJ
Haematologica; 2020 Sep; 105(9):2286-2297. PubMed ID: 33054053
[TBL] [Abstract][Full Text] [Related]
18. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
19. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
20. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
